With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk A/S Dữ liệu về giá theo thời gian thực
The current price of Novo Nordisk A/S in the market is 1.210.839,25 ₫, with a 24-hour trading volume of 257,56B ₫. The asset's market cap is 5,36P ₫, after moving 0.58% in the last day.
Tokenized Novo Nordisk A/S is trading at 1.238.716,96 ₫, with a tokenized market cap of 101,51B ₫ and a 24-hour trading volume of 29,95B ₫. The tokenized asset has moved -2.88% in the past 24 hours.